Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124


Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL.

Blood. 2012 Jul 5;120(1):166-72. doi: 10.1182/blood-2012-01-402396. Epub 2012 May 24.


Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.


Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.


Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.


JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.


Critical requirement for Stat5 in a mouse model of polycythemia vera.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Apr 12;119(15):3539-49. doi: 10.1182/blood-2011-03-345215. Epub 2011 Dec 5.


Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.


The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H.

Blood. 2008 Sep 15;112(6):2429-38. doi: 10.1182/blood-2008-02-137877. Epub 2008 Jul 8.


Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.

Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13.


Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.

Ishii T, Zhao Y, Sozer S, Shi J, Zhang W, Hoffman R, Xu M.

Exp Hematol. 2007 Nov;35(11):1633-40. Epub 2007 Aug 30.


Efficacy of vorinostat in a murine model of polycythemia vera.

Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, Mohi G.

Blood. 2012 Apr 19;119(16):3779-89. doi: 10.1182/blood-2011-02-336743. Epub 2012 Mar 9.


Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD.

Clin Cancer Res. 2010 Sep 1;16(17):4339-52. doi: 10.1158/1078-0432.CCR-10-1092. Epub 2010 Jul 2.


JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.


Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.


Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.


The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Lu M, Xia L, Li Y, Wang X, Hoffman R.

Blood. 2014 Jul 31;124(5):771-9. doi: 10.1182/blood-2013-11-536854. Epub 2014 May 28.


Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.


Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice.

Akada H, Akada S, Hutchison RE, Mohi G.

Haematologica. 2012 Sep;97(9):1389-93. doi: 10.3324/haematol.2011.059113. Epub 2012 Feb 27.


Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.

Fung TK, Cheung AM, Kwong YL, Liang R, Leung AY.

Leuk Res. 2010 Oct;34(10):1390-4. doi: 10.1016/j.leukres.2010.01.028. Epub 2010 Feb 18.


Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.

Yang Y, Akada H, Nath D, Hutchison RE, Mohi G.

Blood. 2016 Jun 30;127(26):3410-23. doi: 10.1182/blood-2015-11-679431. Epub 2016 Apr 14.

Supplemental Content

Support Center